Small Molecules

21 Jun 2019 Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study
21 Jun 2019 Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS
21 Jun 2019 Syntrix Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma
20 Jun 2019 Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
20 Jun 2019 ArTara Therapeutics Announces Initiation of New Immunology Pipeline Program with TARA-002, a Toll-Like Receptor 4 Agonist, Targeting Rare Lymphatic Malformations
20 Jun 2019 Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma
20 Jun 2019 Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
19 Jun 2019 G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
19 Jun 2019 CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
19 Jun 2019 Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association
19 Jun 2019 Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
18 Jun 2019 Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
18 Jun 2019 ArQule Announces Preliminary Results from Its Phase 1/2 Study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an Oral Presentation at the European Society of Human Genetics Conference
18 Jun 2019 Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
18 Jun 2019 Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer
17 Jun 2019 Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
15 Jun 2019 Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
15 Jun 2019 ORYZON Presents Preliminary Dose Finding Results of Phase II Trial With Iadademstat in AML
15 Jun 2019 Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease
15 Jun 2019 Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
15 Jun 2019 Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)
15 Jun 2019 Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
15 Jun 2019 CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
14 Jun 2019 Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
14 Jun 2019 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up